This grant, offered by the NIH HEAL Initiative, aims to support team-based research for developing safe, effective, non-addictive therapeutics to treat pain. Projects should focus on advancing a hit or lead compound through assay development, screening, early optimization, and pharmacokinetic/pharmacodynamic (PK/PD) studies. The ultimate goal is to generate sufficient data to transition promising candidates into later-stage clinical development within five years. Applicants must demonstrate a rigorous biological rationale and provide strong plans for linking therapeutic targets to specific pain indications. This opportunity is broad, welcoming proposals for various pain conditions, including acute, chronic, neuropathic, musculoskeletal, and cancer-related pain.
Opportunity ID: 339726
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-22-052 |
| Funding Opportunity Title: | HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 22, 2022 |
| Last Updated Date: | Apr 22, 2022 |
| Original Closing Date for Applications: | Oct 10, 2023 |
| Current Closing Date for Applications: | Oct 10, 2023 |
| Archive Date: | Nov 15, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments County governments Small businesses Public and State controlled institutions of higher education Independent school districts Private institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Special district governments City or township governments For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the proposal must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, obstetric pain, gynecologic pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-052.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00273611 | May 09, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277524 | Oct 27, 2022 | Oct 10, 2023 | View |
Package 1
Mandatory forms
339726 RR_SF424_5_0-5.0.pdf
339726 PHS398_CoverPageSupplement_5_0-5.0.pdf
339726 RR_OtherProjectInfo_1_4-1.4.pdf
339726 PerformanceSite_4_0-4.0.pdf
339726 RR_KeyPersonExpanded_4_0-4.0.pdf
339726 PHS398_ResearchPlan_4_0-4.0.pdf
339726 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
339726 PHS_Additional_IndirectCosts_2_0-2.0.pdf
339726 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
339726 RR_SF424_5_0-5.0.pdf
339726 PHS398_CoverPageSupplement_5_0-5.0.pdf
339726 RR_OtherProjectInfo_1_4-1.4.pdf
339726 PerformanceSite_4_0-4.0.pdf
339726 RR_KeyPersonExpanded_4_0-4.0.pdf
339726 PHS398_ResearchPlan_5_0-5.0.pdf
339726 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
339726 PHS_Additional_IndirectCosts_2_0-2.0.pdf
339726 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
